Kyntra Bio adds Andrew Singer to board, Maykin Ho departs after eight years
The biopharma company also renewed CEO Thane Wettig's change-in-control and severance agreement for another three years.
SEC filing
Latest
4 stories
Today
Monday, August 31
Kyntra Bio cuts royalty financing cap to $65 million after upfront payment
The company paid $42.6 million upfront to NQ Project Phoebus, L.P. and reduced its maximum obligation under the agreement from $125 million to $65 million.
SEC filing
Thursday, August 13
Kyntra Bio reports Q2 2026 results, reaffirms fourth-quarter trial milestones
Company says roxadustat Phase 3 protocol is finalized and FG-3246 interim analysis remains on track, both targeted for the fourth quarter of 2026.
SEC filing